Aimmune Therapeutics (NASDAQ:AIMT) Cut to “Hold” at ValuEngine

ValuEngine downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a hold rating in a research report released on Thursday morning, ValuEngine reports.

Several other equities analysts have also recently issued reports on AIMT. Cantor Fitzgerald reissued a buy rating and set a $27.00 target price on shares of Spero Therapeutics in a research note on Thursday, May 9th. BidaskClub raised Zillow Group from a buy rating to a strong-buy rating in a research note on Tuesday, July 2nd. Wedbush reissued a buy rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a research note on Tuesday, July 2nd. Zacks Investment Research raised DLH from a sell rating to a hold rating in a research note on Tuesday, July 9th. Finally, Credit Suisse Group reduced their price target on Athene from $67.00 to $57.00 and set an outperform rating on the stock in a research note on Tuesday, May 21st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of Hold and a consensus price target of $41.43.

Shares of AIMT stock opened at $19.00 on Thursday. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.19. Aimmune Therapeutics has a fifty-two week low of $16.95 and a fifty-two week high of $36.12. The company has a 50 day moving average of $20.17. The company has a market capitalization of $1.19 billion, a P/E ratio of -5.18 and a beta of -0.06.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. On average, equities analysts forecast that Aimmune Therapeutics will post -3.77 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc grew its stake in Aimmune Therapeutics by 29.1% in the fourth quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 4,123 shares during the period. Botty Investors LLC purchased a new stake in Aimmune Therapeutics in the first quarter worth $2,505,000. Norges Bank purchased a new stake in Aimmune Therapeutics in the fourth quarter worth $6,035,000. DekaBank Deutsche Girozentrale grew its stake in Aimmune Therapeutics by 21.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 2,700 shares during the period. Finally, Pearl River Capital LLC purchased a new stake in Aimmune Therapeutics in the first quarter worth $28,000. 76.12% of the stock is currently owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Recommended Story: Net Margin – Understanding the Different Kinds of Profit

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit